A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma

被引:49
作者
Bennetto-Hood, Chantelle [1 ]
Tabolt, Glenn [2 ]
Savina, Paul [3 ]
Acosta, Edward P. [1 ]
机构
[1] Univ Alabama Birmingham, Sch Med, Div Clin Pharmacol, Birmingham, AL 35294 USA
[2] GlaxoSmithKline, PTS DMPK, Bioanalyt Sci & Toxicokinet, Res Triangle Pk, NC USA
[3] GlaxoSmithKline, PTS DMPK, Biotransformat & Drug Disposit, Res Triangle Pk, NC USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2014年 / 945卷
关键词
HIV; Integrase inhibitor; Mass spectrometry; Human; Dolutegravir; ANTIRETROVIRAL-NAIVE ADULTS; HIV INTEGRASE INHIBITOR; ONCE-DAILY DOLUTEGRAVIR; DOUBLE-BLIND; RALTEGRAVIR; PHARMACOKINETICS; S/GSK1349572;
D O I
10.1016/j.jchromb.2013.11.054
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) assay was developed and validated to facilitate the assessment of clinical pharmacokinetics of dolutegravir (DTG) in plasma samples. This work describes an assay system requiring only a 20 mu L aliquot of human plasma that is subjected to a simple acetonitrile protein precipitation containing a stably labeled isotope of DTG used as an internal standard. Chromatography was performed on an XBridge C18, 2.1 mm x 50 mm, reversed phase analytical column, using a 60:40 acetonitrile/water mobile phase containing 0.1% formic acid. Detection of the analyte and internal standard was achieved by ESI positive ionization tandem mass spectrometry. The precursor/product transitions (m/z) monitored were 420.1/136.0 and 428.1/283.1 for DTG and DIG-IS, respectively. The dynamic range of this assay extends from 5 to 10,000 ng/mL, with a mean coefficient of determination (r, mean +/- SD) of 0.9996 +/- 0.0003. The mean precision values for calibration standards ranged from 0.7 to 4.1%, while accuracy values were 98.3 to 102.0%. Validation results demonstrated high accuracy (<= 6.5% deviation) and high precision (<= 9.1% CV) for the quality control samples. This assay system provides an accurate, precise, and sensitive method for DTG quantitation and was successfully applied to clinical research samples as part of a phase I/II pediatric clinical trial. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 15 条
[1]   Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].
Cahn, Pedro ;
Pozniak, Anton L. ;
Mingrone, Horacio ;
Shuldyakov, Andrey ;
Brites, Carlos ;
Andrade-Villanueva, Jaime F. ;
Richmond, Gary ;
Beltran Buendia, Carlos ;
Fourie, Jan ;
Ramgopal, Moti ;
Hagins, Debbie ;
Felizarta, Franco ;
Madruga, Jose ;
Reuter, Tania ;
Newman, Tamara ;
Small, Catherine B. ;
Lombaard, John ;
Grinsztejn, Beatriz ;
Dorey, David ;
Underwood, Mark ;
Griffith, Sandy ;
Min, Sherene .
LANCET, 2013, 382 (9893) :700-708
[2]   Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans [J].
Castellino, Stephen ;
Moss, Lee ;
Wagner, David ;
Borland, Julie ;
Song, Ivy ;
Chen, Shuguang ;
Lou, Yu ;
Min, Sherene S. ;
Goljer, Igor ;
Culp, Amanda ;
Piscitelli, Stephen C. ;
Savina, Paul M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) :3536-3546
[3]   Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study [J].
Eron, Joseph J. ;
Clotet, Bonaventura ;
Durant, Jacques ;
Katlama, Christine ;
Kumar, Princy ;
Lazzarin, Adriano ;
Poizot-Martin, Isabelle ;
Richmond, Gary ;
Soriano, Vincent ;
Ait-Khaled, Mounir ;
Fujiwara, Tamio ;
Huang, Jenny ;
Min, Sherene ;
Vavro, Cindy ;
Yeo, Jane .
JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (05) :740-748
[4]  
Food and Drug Administration, 2001, GUID IND BIOANALYTIC
[5]   Dolutegravir for the treatment of HIV [J].
Katlama, Christine ;
Murphy, Robert .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (04) :523-530
[6]   Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers [J].
Min, Sherene ;
Song, Ivy ;
Borland, Julie ;
Chen, Shuguang ;
Lou, Yu ;
Fujiwara, Tamio ;
Piscitelli, Stephen C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :254-258
[7]   Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers [J].
Patel, Parul ;
Song, Ivy ;
Borland, Julie ;
Patel, Apurva ;
Lou, Yu ;
Chen, Shuguang ;
Wajima, Toshihiro ;
Peppercorn, Amanda ;
Min, Sherene S. ;
Piscitelli, Stephen C. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (07) :1567-1572
[8]   Integrase inhibitors to treat HIV/AIDS [J].
Pommier, Y ;
Johnson, AA ;
Marchand, C .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) :236-248
[9]   Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study [J].
Raffi, Francois ;
Rachlis, Anita ;
Stellbrink, Hans-Juergen ;
Hardy, W. David ;
Torti, Carlo ;
Orkin, Chloe ;
Bloch, Mark ;
Podzamczer, Daniel ;
Pokrovsky, Vadim ;
Pulido, Federico ;
Almond, Steve ;
Margolis, David ;
Brennan, Clare ;
Min, Sherene .
LANCET, 2013, 381 (9868) :735-743
[10]   In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor [J].
Reese, Melinda J. ;
Savina, Paul M. ;
Generaux, Grant T. ;
Tracey, Helen ;
Humphreys, Joan E. ;
Kanaoka, Eri ;
Webster, Lindsey O. ;
Harmon, Kelly A. ;
Clarke, James D. ;
Polli, Joseph W. .
DRUG METABOLISM AND DISPOSITION, 2013, 41 (02) :353-361